Sanofi Pasteur: The vaccines division of Sanofi-Aventis Group

Image of a dancing adolescent girl.

About Menactra vaccine

Menactra vaccine is a safe and effective vaccine that helps protect against meningococcal disease, including meningococcal meningitis and meningococcal sepsis.3,4,14

Meningococcal disease is rare.8 But just how serious is it? Did you know that:

  • Up to 1 in 5 survivors suffer brain damage, amputations, kidney damage, and more4,10-12
  • As many as 1 in 8 people who get the disease die from it4,19
  • Teenagers and young adults are more prone to getting the disease4
  • The disease can kill a child in just 24 hours16
  • It’s difficult to diagnose because most common symptoms are similar to those of the influenza (flu)2,4,13,15

Menactra vaccine can reduce your child’s chances of getting meningococcal disease.3,14 The vaccine is produced by Sanofi Pasteur Inc. with almost 42 million doses distributed in the United States since 2005. 5

CDC recommendations

The Centers for Disease Control and Prevention (CDC) have provided an information statement with important facts about meningococcal vaccines.

Click the link below to download:

PLEASE NOTE

By clicking on this link, you will be leaving this Sanofi Pasteur website and going to another, entirely independent website. Sanofi Pasteur provides this link as a service to its website visitors; however, it takes no responsibility for the information presented on any website but its own.

This link has opened in a new window. To return to your original site, please close this new window.

Click here to go to the page you requested. Close window and return to site.


Important Safety Information

Indication

Menactra vaccine is given to people 9 months through 55 years of age to help prevent meningococcal disease (including meningitis) caused by certain strains of meningococcal bacteria. Menactra vaccine is not indicated for the prevention of meningitis caused by meningococcal strains not contained in the vaccine.

Safety Information

Side effects to Menactra vaccine include injection site pain, redness, swelling, headache and tiredness. In infants, irritability, crying, drowsiness, loss of appetite, and diarrhea. Other side effects may occur.

Vaccination should be avoided by persons with known hypersensitivity (severe allergic reaction) to any ingredient of the vaccine. Persons previously diagnosed with Guillain-Barré syndrome (GBS - severe muscle weakness) may have an increased chance of getting GBS following vaccination. Vaccination with Menactra vaccine may not protect all individuals.

For more information about Menactra vaccine, talk to your health care professional.